首页 > 最新文献

Saudi Journal of Gastroenterology最新文献

英文 中文
Elevated Hepatitis B virus RNA levels in hepatocellular carcinoma patients compared to cirrhotic individuals: A propensity score matched analysis. 与肝硬化患者相比,肝细胞癌患者体内乙型肝炎病毒 RNA 水平升高:倾向得分匹配分析
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-07-24 DOI: 10.4103/sjg.sjg_16_24
Yuying Wang, Juanli Wu, Yushuang Zhang, Lei Wang, Tao Li

Background: To delineate the levels of serum Hepatitis B virus (HBV) RNA in patients with HBV-related hepatocellular carcinoma (HCC) and study comparisons with those of individuals afflicted with cirrhosis.

Methods: Adult patients diagnosed with HBV-related cirrhosis or HCC (initial diagnosis) were enrolled in the cross-sectional study. Serum HBV DNA level was quantified through a real-time polymerase chain reaction assay with a lower limit of quantification (LLQ) of 20 IU/ml. Additionally, serum HBV RNA was quantified employing RNA real-time fluorescence thermostatic amplification detection technology with LLQ of 100 copies/ml. Propensity score matching (PSM) was conducted to ensure balance in between-group confounders.

Results: A total of 187 patients (47 with HCC and 140 with cirrhosis) were recruited, among whom 140 (74.9%) had undergone antiviral therapy prior to their inclusion, with varying durations. Serum HBV RNA was detectable in 89.4% of HCC patients at the time of carcinoma diagnosis. After PSM, individuals with HCC exhibited significantly elevated levels of serum HBV DNA and HBV RNA compared to those with cirrhosis (median lgHBV RNA 3.1 vs 2.0 copies/ml, P = 0.001). Subgroup analysis, including 38 patients who exhibited ultrasensitive HBV DNA negativity, revealed similar results (median lgHBV RNA 3.0 vs 0.0 copies/ml, P < 0.001).

Conclusions: Serum HBV RNA levels were significantly higher in HBV-related HCC patients compared to cirrhotic patients. The presence of serum HBV RNA positivity or elevated levels was associated with the onset of HCC.

背景:目的:确定与 HBV 相关的肝细胞癌(HCC)患者的血清乙型肝炎病毒(HBV)RNA 水平,并将其与肝硬化患者进行比较:这项横断面研究招募了被诊断为 HBV 相关肝硬化或 HCC(初次诊断)的成人患者。血清 HBV DNA 水平通过实时聚合酶链反应测定法进行定量,定量下限(LLQ)为 20 IU/ml。此外,血清 HBV RNA 采用 RNA 实时荧光恒温扩增检测技术进行定量,定量下限为 100 拷贝/毫升。进行倾向评分匹配(PSM)以确保组间混杂因素的平衡:共招募了 187 名患者(47 名 HCC 患者和 140 名肝硬化患者),其中 140 人(74.9%)在入组前接受过抗病毒治疗,治疗时间长短不一。89.4% 的 HCC 患者在确诊为癌症时可检测到血清 HBV RNA。PSM 后,与肝硬化患者相比,HCC 患者的血清 HBV DNA 和 HBV RNA 水平明显升高(lgHBV RNA 中位数为 3.1 vs 2.0 copies/ml,P = 0.001)。包括38名HBV DNA超敏阴性患者在内的亚组分析显示了相似的结果(lgHBV RNA中位数为3.0 vs 0.0拷贝/毫升,P < 0.001):结论:与肝硬化患者相比,HBV 相关 HCC 患者的血清 HBV RNA 水平明显更高。血清 HBV RNA 阳性或水平升高与 HCC 的发病有关。
{"title":"Elevated Hepatitis B virus RNA levels in hepatocellular carcinoma patients compared to cirrhotic individuals: A propensity score matched analysis.","authors":"Yuying Wang, Juanli Wu, Yushuang Zhang, Lei Wang, Tao Li","doi":"10.4103/sjg.sjg_16_24","DOIUrl":"10.4103/sjg.sjg_16_24","url":null,"abstract":"<p><strong>Background: </strong>To delineate the levels of serum Hepatitis B virus (HBV) RNA in patients with HBV-related hepatocellular carcinoma (HCC) and study comparisons with those of individuals afflicted with cirrhosis.</p><p><strong>Methods: </strong>Adult patients diagnosed with HBV-related cirrhosis or HCC (initial diagnosis) were enrolled in the cross-sectional study. Serum HBV DNA level was quantified through a real-time polymerase chain reaction assay with a lower limit of quantification (LLQ) of 20 IU/ml. Additionally, serum HBV RNA was quantified employing RNA real-time fluorescence thermostatic amplification detection technology with LLQ of 100 copies/ml. Propensity score matching (PSM) was conducted to ensure balance in between-group confounders.</p><p><strong>Results: </strong>A total of 187 patients (47 with HCC and 140 with cirrhosis) were recruited, among whom 140 (74.9%) had undergone antiviral therapy prior to their inclusion, with varying durations. Serum HBV RNA was detectable in 89.4% of HCC patients at the time of carcinoma diagnosis. After PSM, individuals with HCC exhibited significantly elevated levels of serum HBV DNA and HBV RNA compared to those with cirrhosis (median lgHBV RNA 3.1 vs 2.0 copies/ml, P = 0.001). Subgroup analysis, including 38 patients who exhibited ultrasensitive HBV DNA negativity, revealed similar results (median lgHBV RNA 3.0 vs 0.0 copies/ml, P < 0.001).</p><p><strong>Conclusions: </strong>Serum HBV RNA levels were significantly higher in HBV-related HCC patients compared to cirrhotic patients. The presence of serum HBV RNA positivity or elevated levels was associated with the onset of HCC.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"294-301"},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141761954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of preoperative transjugular intrahepatic portosystemic shunt prior to extrahepatic, abdominal surgery in patients with cirrhosis. 肝硬化患者肝外、腹部手术前经颈静脉肝内门体分流术的系统性回顾。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.4103/sjg.sjg_114_24
Mahnur Haider, Yakub Ali Nur, Hareem Syed, Kashif Khan

Background: Extrahepatic, abdominal surgery in patients with cirrhosis is associated with high morbidity and mortality. This systematic review presents the current evidence available on the utility of a preoperative transjugular intrahepatic portosystemic shunt (TIPS), assessed by its effect on surgical candidacy and postoperative mortality and morbidity in patients with cirrhosis undergoing extrahepatic, abdominal surgery.

Methods: MEDLINE, EMBASE, Cochrane Library and Web of Science databases were searched till 2022 to identify studies. Studies that reported characteristics and outcomes of participants with cirrhosis that had a TIPS inserted in preparation for extrahepatic, abdominal surgery, were included.

Results: Twenty-one studies (292 patients) were included, of which three were comparative studies and the remaining case series or case reports. A TIPS was inserted in 190 patients prior to surgery. At least one clinical sign of portal hypertension identified by ascites, varices, and/or hepatic encephalopathy were present in all patients except one patient. Fifty eight percent had decompensated cirrhosis. TIPS insertion was successful in all patients. Eighty-nine percent of patients underwent surgery. The cumulative 30-day postoperative mortality was 2% (3/148). There were 97 complications reported in 168 patients (57%). In the three comparative studies, there was no difference in mortality or morbidity among patients who underwent TIPS prior to surgery compared to those who did not undergo TIPS prior to surgery.

Conclusion: Preoperative TIPS has been used to improve surgical candidacy in patients with cirrhosis undergoing extrahepatic, abdominal surgery, while reducing complications of portal hypertension. However, there is not enough evidence to support that TIPS insertion prior to extrahepatic, abdominal surgery significantly improves surgical outcomes in patients with cirrhosis and further studies are needed.

背景:肝硬化患者的肝外腹腔手术与高发病率和高死亡率有关。本系统性综述介绍了关于术前经颈静脉肝内门体分流术(TIPS)效用的现有证据,根据其对接受肝外腹腔手术的肝硬化患者的手术候选资格、术后死亡率和发病率的影响进行评估:方法:检索了截至 2022 年的 MEDLINE、EMBASE、Cochrane Library 和 Web of Science 数据库,以确定相关研究。结果:21 项研究(292 名患者)发现,肝硬化患者在准备肝外腹腔手术时插入了 TIPS:结果:共纳入 21 项研究(292 名患者),其中 3 项为对比研究,其余为病例系列或病例报告。有 190 名患者在手术前植入了 TIPS。除一名患者外,所有患者至少有一种门脉高压的临床表现,包括腹水、静脉曲张和/或肝性脑病。58%的患者患有失代偿期肝硬化。所有患者都成功插入了 TIPS。89% 的患者接受了手术。术后30天累计死亡率为2%(3/148)。据报告,168 名患者中出现了 97 例并发症(占 57%)。在三项对比研究中,术前接受TIPS治疗的患者与术前未接受TIPS治疗的患者在死亡率或发病率方面没有差异:结论:术前 TIPS 用于改善肝硬化患者接受肝外腹腔手术的手术时机,同时减少门静脉高压并发症。然而,目前还没有足够的证据证明在肝外腹腔手术前植入 TIPS 能显著改善肝硬化患者的手术效果,因此还需要进一步的研究。
{"title":"A systematic review of preoperative transjugular intrahepatic portosystemic shunt prior to extrahepatic, abdominal surgery in patients with cirrhosis.","authors":"Mahnur Haider, Yakub Ali Nur, Hareem Syed, Kashif Khan","doi":"10.4103/sjg.sjg_114_24","DOIUrl":"10.4103/sjg.sjg_114_24","url":null,"abstract":"<p><strong>Background: </strong>Extrahepatic, abdominal surgery in patients with cirrhosis is associated with high morbidity and mortality. This systematic review presents the current evidence available on the utility of a preoperative transjugular intrahepatic portosystemic shunt (TIPS), assessed by its effect on surgical candidacy and postoperative mortality and morbidity in patients with cirrhosis undergoing extrahepatic, abdominal surgery.</p><p><strong>Methods: </strong>MEDLINE, EMBASE, Cochrane Library and Web of Science databases were searched till 2022 to identify studies. Studies that reported characteristics and outcomes of participants with cirrhosis that had a TIPS inserted in preparation for extrahepatic, abdominal surgery, were included.</p><p><strong>Results: </strong>Twenty-one studies (292 patients) were included, of which three were comparative studies and the remaining case series or case reports. A TIPS was inserted in 190 patients prior to surgery. At least one clinical sign of portal hypertension identified by ascites, varices, and/or hepatic encephalopathy were present in all patients except one patient. Fifty eight percent had decompensated cirrhosis. TIPS insertion was successful in all patients. Eighty-nine percent of patients underwent surgery. The cumulative 30-day postoperative mortality was 2% (3/148). There were 97 complications reported in 168 patients (57%). In the three comparative studies, there was no difference in mortality or morbidity among patients who underwent TIPS prior to surgery compared to those who did not undergo TIPS prior to surgery.</p><p><strong>Conclusion: </strong>Preoperative TIPS has been used to improve surgical candidacy in patients with cirrhosis undergoing extrahepatic, abdominal surgery, while reducing complications of portal hypertension. However, there is not enough evidence to support that TIPS insertion prior to extrahepatic, abdominal surgery significantly improves surgical outcomes in patients with cirrhosis and further studies are needed.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"275-282"},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-flow nasal cannula oxygen therapy is equally effective to noninvasive ventilation for mild-moderate acute respiratory distress syndrome in patients with acute pancreatitis: A single-center, retrospective cohort study. 对于急性胰腺炎患者的轻中度急性呼吸窘迫综合征,高流量鼻插管氧疗与无创通气同样有效:单中心回顾性队列研究。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-05-30 DOI: 10.4103/sjg.sjg_24_24
Qingcheng Zhu, Wenzhen Zhou, Bingyu Ling, Huihui Wang, Dingyu Tan

Background: The use of high-flow nasal cannula (HFNC) oxygen therapy is gaining popularity for the treatment of acute hypoxic respiratory failure. However, limited evidence exists regarding the effectiveness of HFNC for acute respiratory distress syndrome (ARDS) in patients with acute pancreatitis (AP).

Methods: This retrospective analysis focused on AP patients with mild-moderate ARDS, who were treated with either HFNC or noninvasive ventilation (NIV) in the emergency medicine department, from January 2020 to December 2022. The primary endpoint was treatment failure, defined as either invasive ventilation or a switch to any other study treatment (NIV for patients in the NFNC group and vice versa).

Results: A total of 146 patients with AP (68 in the HFNC group and 78 in the NIV group) were included in this study. The treatment failure rate in the HFNC group was 17.6% and 19.2% in the NIV group - a risk difference of -1.6% (95% CI, -11.3 to 14.0%; P = 0.806). The most common causes of failure in the HFNC group were aggravation of respiratory distress and hypoxemia. However, in the NIV group, the most common reasons for failure were treatment intolerance and exacerbation of respiratory distress. Treatment intolerance in the HFNC group was significantly lower than that in the NIV group (16.7% vs 60.0%, 95% CI -66.8 to -6.2; P = 0.023). Multivariate logistic regression analysis showed that body mass index (≥28), acute physiology and chronic health evaluation II score (≥15), partial arterial oxygen tension/fraction of inspired oxygen (≤200), and respiratory rate (≥32/min) at 1 hour were independent predictors of HFNC failure.

Conclusion: In AP patients with mild-moderate ARDS, the usage of HFNC did not lead to a higher rate of treatment failure when compared to NIV. HFNC is an ideal choice of respiratory support for patients with NIV intolerance, but clinical application should pay attention to the influencing factors of its treatment failure.

背景:使用高流量鼻插管(HFNC)氧疗治疗急性缺氧性呼吸衰竭越来越受欢迎。然而,关于高流量鼻插管治疗急性胰腺炎(AP)患者急性呼吸窘迫综合征(ARDS)的有效性,目前证据有限:这项回顾性分析主要针对 2020 年 1 月至 2022 年 12 月期间在急诊科接受 HFNC 或无创通气(NIV)治疗的轻中度 ARDS 急性胰腺炎患者。主要终点是治疗失败,定义为有创通气或改用任何其他研究疗法(NFNC 组患者改用 NIV,反之亦然):本研究共纳入 146 名 AP 患者(高频通气治疗组 68 人,NIV 组 78 人)。HFNC组的治疗失败率为17.6%,NIV组为19.2%,风险差异为-1.6%(95% CI,-11.3%至14.0%;P = 0.806)。HFNC 组最常见的失败原因是呼吸窘迫加重和低氧血症。而在 NIV 组,最常见的失败原因是治疗不耐受和呼吸窘迫加重。HFNC 组的治疗不耐受率明显低于 NIV 组(16.7% vs 60.0%,95% CI -66.8 to -6.2;P = 0.023)。多变量逻辑回归分析显示,体重指数(≥28)、急性生理学和慢性健康评估 II 评分(≥15)、动脉血氧分压/吸入氧分压(≤200)和 1 小时呼吸频率(≥32/分钟)是预测 HFNC 失败的独立因素:结论:在轻度-中度 ARDS 的 AP 患者中,与 NIV 相比,使用 HFNC 不会导致更高的治疗失败率。HFNC是不耐受NIV患者呼吸支持的理想选择,但临床应用时应注意其治疗失败的影响因素。
{"title":"High-flow nasal cannula oxygen therapy is equally effective to noninvasive ventilation for mild-moderate acute respiratory distress syndrome in patients with acute pancreatitis: A single-center, retrospective cohort study.","authors":"Qingcheng Zhu, Wenzhen Zhou, Bingyu Ling, Huihui Wang, Dingyu Tan","doi":"10.4103/sjg.sjg_24_24","DOIUrl":"10.4103/sjg.sjg_24_24","url":null,"abstract":"<p><strong>Background: </strong>The use of high-flow nasal cannula (HFNC) oxygen therapy is gaining popularity for the treatment of acute hypoxic respiratory failure. However, limited evidence exists regarding the effectiveness of HFNC for acute respiratory distress syndrome (ARDS) in patients with acute pancreatitis (AP).</p><p><strong>Methods: </strong>This retrospective analysis focused on AP patients with mild-moderate ARDS, who were treated with either HFNC or noninvasive ventilation (NIV) in the emergency medicine department, from January 2020 to December 2022. The primary endpoint was treatment failure, defined as either invasive ventilation or a switch to any other study treatment (NIV for patients in the NFNC group and vice versa).</p><p><strong>Results: </strong>A total of 146 patients with AP (68 in the HFNC group and 78 in the NIV group) were included in this study. The treatment failure rate in the HFNC group was 17.6% and 19.2% in the NIV group - a risk difference of -1.6% (95% CI, -11.3 to 14.0%; P = 0.806). The most common causes of failure in the HFNC group were aggravation of respiratory distress and hypoxemia. However, in the NIV group, the most common reasons for failure were treatment intolerance and exacerbation of respiratory distress. Treatment intolerance in the HFNC group was significantly lower than that in the NIV group (16.7% vs 60.0%, 95% CI -66.8 to -6.2; P = 0.023). Multivariate logistic regression analysis showed that body mass index (≥28), acute physiology and chronic health evaluation II score (≥15), partial arterial oxygen tension/fraction of inspired oxygen (≤200), and respiratory rate (≥32/min) at 1 hour were independent predictors of HFNC failure.</p><p><strong>Conclusion: </strong>In AP patients with mild-moderate ARDS, the usage of HFNC did not lead to a higher rate of treatment failure when compared to NIV. HFNC is an ideal choice of respiratory support for patients with NIV intolerance, but clinical application should pay attention to the influencing factors of its treatment failure.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"302-309"},"PeriodicalIF":1.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is HBV RNA a new endpoint of HBV cure? HBV RNA 是 HBV 治愈的新终点吗?
IF 2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 Epub Date: 2024-09-02 DOI: 10.4103/sjg.sjg_274_24
Henry Lik Yuen Chan
{"title":"Is HBV RNA a new endpoint of HBV cure?","authors":"Henry Lik Yuen Chan","doi":"10.4103/sjg.sjg_274_24","DOIUrl":"10.4103/sjg.sjg_274_24","url":null,"abstract":"","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"273-274"},"PeriodicalIF":2.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of cap-mounted clips as a primary hemostatic modality in nonvariceal upper gastrointestinal bleeding: A systematic review and meta-analysis of randomized trials. 使用带帽夹作为非静脉曲张性上消化道出血的主要止血方式:随机试验的系统回顾和荟萃分析。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-10 DOI: 10.4103/sjg.sjg_86_24
Ali A Alali, Majid A Almadi, Myriam Martel, Alan N Barkun

Background: Cap-mounted-clips, especially Over-The-Scope-Clip (OTSC™), are recommended for recurrent nonvariceal upper gastrointestinal bleeding (NVUGIB). There has been recent interest in their use as an initial hemostatic modality. We performed a systematic review of randomized controlled trials (RCTs) assessing cap-mounted clips' efficacy as a primary hemostatic modality in NVUGIB.

Methods: A literature search of MEDLINE, EMBASE, and ISI Web of Science databases up to April 2024 identified RCTs comparing cap-mounted clips to standard endoscopic therapy (SET) as a primary hemostatic modality in NVUGIB. The primary endpoint was the composite outcome of further bleeding (persistent or recurrent) at 30 days. Secondary outcomes included persistent bleeding at index endoscopy and 30-day rebleeding, individually. Other pertinent outcomes were also recorded. A meta-analysis was performed to determine pooled risk ratios (RRs), comparing cap-mounted clip to SET. Out of 516 citations, five RCTs (n = 555), all assessing OTSC™, were included.

Results: The composite outcome of further bleeding was lower with cap-mounted clip versus SET (RR = 0.33 [95% confidence interval {CI}: 0.20-0.54]). There was no difference in persistent bleeding at initial endoscopy (RR = 0.30 [95% CI: 0.07-1.30]), but 30-day rebleeding was lower with cap-mounted clip (RR = 0.38 [95% CI: 0.21-0.70]). There were no differences in other outcomes. Grading of the evidence ranged from very low to moderate, mainly due to risk of bias and imprecision.

Conclusions: Cap-mounted clips may be an efficacious primary hemostatic modality, associated with a lower further bleeding at 30 days compared to SET in NVUGIB. However, due to limitations in existing evidence, further research must better characterize an optimal subgroup of patients benefiting most from this approach before adopting its routine use.

背景:对于复发性非静脉曲张性上消化道出血(NVUGIB),推荐使用帽式夹,尤其是镜下夹 (OTSC™)。最近,人们开始关注将其用作初始止血方式。我们对评估帽式夹作为 NVUGIB 主要止血方式疗效的随机对照试验 (RCT) 进行了系统性回顾:截至 2024 年 4 月,我们对 MEDLINE、EMBASE 和 ISI Web of Science 数据库进行了文献检索,发现了将帽式夹与标准内镜疗法 (SET) 作为 NVUGIB 主要止血方式进行比较的 RCT。主要终点是30天后进一步出血(持续性或复发性)的综合结果。次要结局包括指数内镜检查时的持续出血和 30 天后的再出血。其他相关结果也被记录在案。我们进行了一项荟萃分析,以确定将帽式夹与 SET 进行比较的风险比 (RR)。在516篇引用文献中,纳入了5项RCT研究(n = 555),所有研究都对OTSC™进行了评估:结果:帽式夹与SET相比,进一步出血的复合结果更低(RR = 0.33 [95% 置信区间{CI}:0.20-0.54])。初次内镜检查时持续出血的情况没有差异(RR = 0.30 [95% CI:0.07-1.30]),但帽式夹的 30 天再出血率较低(RR = 0.38 [95% CI:0.21-0.70])。其他结果没有差异。证据评分从很低到中等不等,主要原因是存在偏倚风险和不精确性:帽式夹可能是一种有效的主要止血方式,与 SET 相比,NVUGIB 患者 30 天后的进一步出血量更低。然而,由于现有证据的局限性,在常规使用之前,进一步的研究必须更好地确定从这种方法中获益最多的最佳患者亚群。
{"title":"The use of cap-mounted clips as a primary hemostatic modality in nonvariceal upper gastrointestinal bleeding: A systematic review and meta-analysis of randomized trials.","authors":"Ali A Alali, Majid A Almadi, Myriam Martel, Alan N Barkun","doi":"10.4103/sjg.sjg_86_24","DOIUrl":"10.4103/sjg.sjg_86_24","url":null,"abstract":"<p><strong>Background: </strong>Cap-mounted-clips, especially Over-The-Scope-Clip (OTSC™), are recommended for recurrent nonvariceal upper gastrointestinal bleeding (NVUGIB). There has been recent interest in their use as an initial hemostatic modality. We performed a systematic review of randomized controlled trials (RCTs) assessing cap-mounted clips' efficacy as a primary hemostatic modality in NVUGIB.</p><p><strong>Methods: </strong>A literature search of MEDLINE, EMBASE, and ISI Web of Science databases up to April 2024 identified RCTs comparing cap-mounted clips to standard endoscopic therapy (SET) as a primary hemostatic modality in NVUGIB. The primary endpoint was the composite outcome of further bleeding (persistent or recurrent) at 30 days. Secondary outcomes included persistent bleeding at index endoscopy and 30-day rebleeding, individually. Other pertinent outcomes were also recorded. A meta-analysis was performed to determine pooled risk ratios (RRs), comparing cap-mounted clip to SET. Out of 516 citations, five RCTs (n = 555), all assessing OTSC™, were included.</p><p><strong>Results: </strong>The composite outcome of further bleeding was lower with cap-mounted clip versus SET (RR = 0.33 [95% confidence interval {CI}: 0.20-0.54]). There was no difference in persistent bleeding at initial endoscopy (RR = 0.30 [95% CI: 0.07-1.30]), but 30-day rebleeding was lower with cap-mounted clip (RR = 0.38 [95% CI: 0.21-0.70]). There were no differences in other outcomes. Grading of the evidence ranged from very low to moderate, mainly due to risk of bias and imprecision.</p><p><strong>Conclusions: </strong>Cap-mounted clips may be an efficacious primary hemostatic modality, associated with a lower further bleeding at 30 days compared to SET in NVUGIB. However, due to limitations in existing evidence, further research must better characterize an optimal subgroup of patients benefiting most from this approach before adopting its routine use.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel nomogram for the prediction of perforation during endoscopic submucosal dissection for colorectal neoplasms. 用于预测结直肠肿瘤内镜黏膜下剥离术穿孔的新型提名图。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-06 DOI: 10.4103/sjg.sjg_417_23
Yuxin Zhang, Fang Gu, Xun Liu, Shigang Ding

Background: High perforation risk hinders the widespread adoption of ESD for colorectal neoplasms. This study was performed to determine the risk factors of colorectal endoscopic submucosal dissection (ESD)-induced perforation and develop a predictive model.

Methods: A total of 1046 colorectal neoplasms in 1011 patients were retrospectively enrolled from January 2011 to December 2021, in a single tertiary center as the derivation cohort. We identified independent risk factors for perforation using univariate analysis and multi-variate logistic regression. A nomogram was developed based on the logistic regression model and prospectively applied to 266 colorectal neoplasms as the validation cohort. The performance of the predictive model was evaluated with the receiver operating characteristic curve, calibration plot, and decision curve analysis.

Results: Independent pre-operative factors for colorectal ESD-induced perforation were tumor located in the left colon [odds ratio (OR) 2.39, P = 0.040], size ≥ 40 mm (OR 3.36, P < 0.001), ≥2/3 circumference (OR 7.55, P = 0.004), located across folds (OR 6.26, P < 0.001), and laterally spreading tumor (non-granular type, OR 2.34, P = 0.029; granular type, OR 2.46, P = 0.021). The nomogram model incorporating the pre-operative factors performed well in both the derivation and validation cohorts (areas under the curve of 0.750 and 0.806, respectively). Decision curve analysis demonstrated that the clinical benefit of the nomogram was favorable.

Conclusions: The novel nomogram, developed and prospectively validated, incorporating tumor size, location, and morphology can successfully predict perforation during ESD for colorectal neoplasms.

背景:穿孔的高风险阻碍了ESD治疗结直肠肿瘤的广泛应用。本研究旨在确定结直肠内镜黏膜下剥离术(ESD)诱发穿孔的风险因素,并建立预测模型:方法:2011年1月至2021年12月期间,我们在一个三级中心回顾性登记了1011名患者的1046例结直肠肿瘤,作为衍生队列。我们通过单变量分析和多变量逻辑回归确定了穿孔的独立风险因素。在逻辑回归模型的基础上开发了一个提名图,并对 266 例结肠直肠肿瘤作为验证队列进行了前瞻性应用。通过接收者操作特征曲线、校准图和决策曲线分析评估了预测模型的性能:结果:结肠直肠ESD诱发穿孔的独立术前因素是肿瘤位于左侧结肠[比值比(OR)2.39,P = 0.040]、大小≥40毫米(OR 3.36,P < 0.001)、周长≥2/3(OR 7.55,P = 0.004)、位于褶皱处(OR 6.26,P < 0.001)、肿瘤横向扩散(非颗粒型,OR 2.34,P = 0.029;颗粒型,OR 2.46,P = 0.021)。包含术前因素的提名图模型在推导组和验证组中都表现良好(曲线下面积分别为 0.750 和 0.806)。决策曲线分析表明,该提名图具有良好的临床效益:结论:结合肿瘤大小、位置和形态开发并经前瞻性验证的新型提名图能成功预测结直肠肿瘤ESD手术中的穿孔。
{"title":"A novel nomogram for the prediction of perforation during endoscopic submucosal dissection for colorectal neoplasms.","authors":"Yuxin Zhang, Fang Gu, Xun Liu, Shigang Ding","doi":"10.4103/sjg.sjg_417_23","DOIUrl":"10.4103/sjg.sjg_417_23","url":null,"abstract":"<p><strong>Background: </strong>High perforation risk hinders the widespread adoption of ESD for colorectal neoplasms. This study was performed to determine the risk factors of colorectal endoscopic submucosal dissection (ESD)-induced perforation and develop a predictive model.</p><p><strong>Methods: </strong>A total of 1046 colorectal neoplasms in 1011 patients were retrospectively enrolled from January 2011 to December 2021, in a single tertiary center as the derivation cohort. We identified independent risk factors for perforation using univariate analysis and multi-variate logistic regression. A nomogram was developed based on the logistic regression model and prospectively applied to 266 colorectal neoplasms as the validation cohort. The performance of the predictive model was evaluated with the receiver operating characteristic curve, calibration plot, and decision curve analysis.</p><p><strong>Results: </strong>Independent pre-operative factors for colorectal ESD-induced perforation were tumor located in the left colon [odds ratio (OR) 2.39, P = 0.040], size ≥ 40 mm (OR 3.36, P < 0.001), ≥2/3 circumference (OR 7.55, P = 0.004), located across folds (OR 6.26, P < 0.001), and laterally spreading tumor (non-granular type, OR 2.34, P = 0.029; granular type, OR 2.46, P = 0.021). The nomogram model incorporating the pre-operative factors performed well in both the derivation and validation cohorts (areas under the curve of 0.750 and 0.806, respectively). Decision curve analysis demonstrated that the clinical benefit of the nomogram was favorable.</p><p><strong>Conclusions: </strong>The novel nomogram, developed and prospectively validated, incorporating tumor size, location, and morphology can successfully predict perforation during ESD for colorectal neoplasms.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"228-235"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The combined pioglitazone and topiramate therapy for management of pediatric patients with severe MASLD. 吡格列酮和托吡酯联合疗法用于治疗儿童重度 MASLD 患者。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-10 DOI: 10.4103/sjg.sjg_428_23
Callen Conroy, Aurelia Radulescu, Suzanna L Attia, Nathan Shelman, James T Lee, Roberto Galuppo Monticelli, Sara Hall, Rohit Kohli, Samir Softic

Background: Metabolic dysfunction associated steatotic liver disease (MASLD) is the most common cause of chronic hepatitis in adult and pediatric patients. Adolescents with severe MASLD can demonstrate a more aggressive disease phenotype as they more commonly develop liver fibrosis than BMI matched adults. Therefore, MASLD is the fastest growing indication for liver transplants in young adults.

Methods: Pioglitazone has been shown to improve liver histology in adult patients with MASLD, and in some studies, it attenuated liver fibrosis. Despite its perceived efficacy, pioglitazone is not widely used, likely due to its side effect profile, specifically increased weight gain. Topiramate lowers body weight in adolescents and in combination with phentermine, is one of the few FDA-approved medications for the management of obesity in children over 12 years of age. We performed a retrospective review of the outcomes in pediatric patients with severe MASLD, treated with the combined pioglitazone and topiramate therapy.

Results: Here, we report a case series of seven adolescents with severe MASLD and ≥F2 liver fibrosis treated with the combined pioglitazone and topiramate therapy. The combined therapy improved mean serum ALT from 165 ± 80 U/L to 89 ± 62 U/L after 12 months mean duration of treatment. One patient who completed 24 months of the combined therapy demonstrated a decrease in liver stiffness from 8.9 kPa to 5.6 kPa, as assessed by FibroScan elastography. There was a significant increase in body weight during this time, however, body mass index as a percentage of the 95 th percentile adjusted for age and gender did not increase significantly, 151 ± 29% vs. 152 ± 28%. Moreover, waist circumference, mid-upper arm circumference, percent body fat, and muscle mass were not significantly different before and after treatment. Serum lipid levels and hemoglobin A1c also did not change with the treatment.

Conclusion: In summary, this case series provides encouraging results about the efficacy of the combined pioglitazone and topiramate therapy for the management of adolescents with severe MASLD, which should be further explored in clinical studies.

背景:代谢功能障碍相关性脂肪性肝病(MASLD)是成人和儿童慢性肝炎最常见的病因。与体重指数相匹配的成年人相比,患有严重代谢性脂肪肝的青少年更容易发展为肝纤维化,从而表现出更具侵袭性的疾病表型。因此,MASLD 是青少年肝移植中增长最快的适应症:方法:研究表明,吡格列酮可改善MASLD成年患者的肝脏组织学,在一些研究中,吡格列酮还可减轻肝纤维化。尽管疗效显著,但吡格列酮并未得到广泛应用,这可能是由于它的副作用,尤其是体重增加。托吡酯可降低青少年的体重,与芬特明联用,是美国食品药品管理局批准的少数几种治疗 12 岁以上儿童肥胖症的药物之一。我们对使用吡格列酮和托吡酯联合治疗的重度MASLD儿科患者的疗效进行了回顾性研究:在此,我们报告了七名患有严重MASLD且肝纤维化≥F2的青少年患者接受吡格列酮和托吡酯联合治疗的系列病例。平均疗程为 12 个月后,联合疗法使平均血清 ALT 从 165 ± 80 U/L降至 89 ± 62 U/L。一名完成了 24 个月联合治疗的患者通过纤维扫描弹性成像评估显示,肝脏硬度从 8.9 kPa 降至 5.6 kPa。在此期间,患者的体重有明显增加,但体重指数(按年龄和性别调整后占第 95 百分位数的百分比)并没有明显增加,分别为 151 ± 29% 和 152 ± 28%。此外,腰围、中上臂围、体脂百分比和肌肉质量在治疗前后也没有明显差异。血清脂质水平和血红蛋白 A1c 在治疗后也没有变化:总之,本系列病例为吡格列酮和托吡酯联合治疗青少年重度MASLD提供了令人鼓舞的疗效,应在临床研究中进一步探讨。
{"title":"The combined pioglitazone and topiramate therapy for management of pediatric patients with severe MASLD.","authors":"Callen Conroy, Aurelia Radulescu, Suzanna L Attia, Nathan Shelman, James T Lee, Roberto Galuppo Monticelli, Sara Hall, Rohit Kohli, Samir Softic","doi":"10.4103/sjg.sjg_428_23","DOIUrl":"10.4103/sjg.sjg_428_23","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction associated steatotic liver disease (MASLD) is the most common cause of chronic hepatitis in adult and pediatric patients. Adolescents with severe MASLD can demonstrate a more aggressive disease phenotype as they more commonly develop liver fibrosis than BMI matched adults. Therefore, MASLD is the fastest growing indication for liver transplants in young adults.</p><p><strong>Methods: </strong>Pioglitazone has been shown to improve liver histology in adult patients with MASLD, and in some studies, it attenuated liver fibrosis. Despite its perceived efficacy, pioglitazone is not widely used, likely due to its side effect profile, specifically increased weight gain. Topiramate lowers body weight in adolescents and in combination with phentermine, is one of the few FDA-approved medications for the management of obesity in children over 12 years of age. We performed a retrospective review of the outcomes in pediatric patients with severe MASLD, treated with the combined pioglitazone and topiramate therapy.</p><p><strong>Results: </strong>Here, we report a case series of seven adolescents with severe MASLD and ≥F2 liver fibrosis treated with the combined pioglitazone and topiramate therapy. The combined therapy improved mean serum ALT from 165 ± 80 U/L to 89 ± 62 U/L after 12 months mean duration of treatment. One patient who completed 24 months of the combined therapy demonstrated a decrease in liver stiffness from 8.9 kPa to 5.6 kPa, as assessed by FibroScan elastography. There was a significant increase in body weight during this time, however, body mass index as a percentage of the 95 th percentile adjusted for age and gender did not increase significantly, 151 ± 29% vs. 152 ± 28%. Moreover, waist circumference, mid-upper arm circumference, percent body fat, and muscle mass were not significantly different before and after treatment. Serum lipid levels and hemoglobin A1c also did not change with the treatment.</p><p><strong>Conclusion: </strong>In summary, this case series provides encouraging results about the efficacy of the combined pioglitazone and topiramate therapy for the management of adolescents with severe MASLD, which should be further explored in clinical studies.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"252-259"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacral nerve stimulation effect on colonic motility in pediatric patients. 骶神经刺激对儿科患者结肠运动的影响
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-15 DOI: 10.4103/sjg.sjg_407_23
Lev Dorfman, Anat Sigal, Khalil El-Chammas, Sherief Mansi, Ajay Kaul

Background: Sacral nerve stimulation (SNS) is a minimally invasive surgical procedure used to treat refractory constipation in children. While its efficacy in improving symptoms has been studied, its effect on colonic motor function remains unclear. This case series explores SNS's impact on colonic motor function in pediatric patients with idiopathic constipation, using high-resolution colonic manometry (HRCM).

Methods: Four pediatric patients with chronic idiopathic constipation underwent SNS placement for intractable symptoms and were subsequently evaluated via HRCM. Clinical characteristics, comorbidities, treatment regimens, and outcomes were reviewed. HRCM was conducted during the SNS-off and SNS-on phases. The motility index (MI) was measured during the SNS-off (fasting and postprandial) and SNS-on phases.

Results: Four pediatric patients aged 8 to 21 years met the inclusion criteria. In three patients, SNS-induced high-amplitude propagating contractions (HAPCs) were noted, and in one patient, low-amplitude propagating contractions (LAPCs) were noted. In one patient, propagating contractions were induced only when SNS was turned on. MI changes with SNS-on were variable among different patients with an increase in MI in two patients after turning SNS on and a decrease in the other two compared with baseline. Adverse effects following SNS placement remained minimal across all cases.

Conclusion: This case series is the first to report SNS effects on colonic motility evaluated by HRCM in pediatrics. We demonstrate that propagating colonic contractions are promptly induced when SNS is turned on. Although the initial effects of SNS on colonic motility were observable, additional investigation is necessary to comprehend the fundamental mechanisms and long-term effectiveness of SNS in pediatric patients.

背景:骶神经刺激术(SNS)是一种用于治疗儿童难治性便秘的微创外科手术。虽然已对其改善症状的疗效进行了研究,但其对结肠运动功能的影响仍不清楚。本病例系列通过使用高分辨率结肠测压法(HRCM)探讨 SNS 对特发性便秘儿科患者结肠运动功能的影响:四名患有慢性特发性便秘的儿科患者因症状难治而接受了 SNS 置入术,随后通过 HRCM 进行了评估。对临床特征、合并症、治疗方案和结果进行了回顾。HRCM 在 SNS 关闭和 SNS 开启阶段进行。在停用 SNS(空腹和餐后)和启用 SNS 阶段测量了运动指数 (MI):结果:四名 8 至 21 岁的儿童患者符合纳入标准。三名患者出现了 SNS 引起的高振幅传播性收缩(HAPCs),一名患者出现了低振幅传播性收缩(LAPCs)。在一名患者中,只有在开启 SNS 时才会诱发传播性收缩。不同患者在开启 SNS 后的心肌收缩率变化不一,其中两名患者在开启 SNS 后心肌收缩率增加,另外两名患者的心肌收缩率与基线相比有所下降。在所有病例中,置入 SNS 后的不良反应仍然很小:本病例系列首次报告了通过 HRCM 评估 SNS 对儿科结肠运动的影响。我们证明,开启 SNS 后可迅速诱发传播性结肠收缩。虽然可以观察到 SNS 对结肠运动的初步影响,但要了解 SNS 在儿科患者中的基本机制和长期效果,还需要进行更多的研究。
{"title":"Sacral nerve stimulation effect on colonic motility in pediatric patients.","authors":"Lev Dorfman, Anat Sigal, Khalil El-Chammas, Sherief Mansi, Ajay Kaul","doi":"10.4103/sjg.sjg_407_23","DOIUrl":"10.4103/sjg.sjg_407_23","url":null,"abstract":"<p><strong>Background: </strong>Sacral nerve stimulation (SNS) is a minimally invasive surgical procedure used to treat refractory constipation in children. While its efficacy in improving symptoms has been studied, its effect on colonic motor function remains unclear. This case series explores SNS's impact on colonic motor function in pediatric patients with idiopathic constipation, using high-resolution colonic manometry (HRCM).</p><p><strong>Methods: </strong>Four pediatric patients with chronic idiopathic constipation underwent SNS placement for intractable symptoms and were subsequently evaluated via HRCM. Clinical characteristics, comorbidities, treatment regimens, and outcomes were reviewed. HRCM was conducted during the SNS-off and SNS-on phases. The motility index (MI) was measured during the SNS-off (fasting and postprandial) and SNS-on phases.</p><p><strong>Results: </strong>Four pediatric patients aged 8 to 21 years met the inclusion criteria. In three patients, SNS-induced high-amplitude propagating contractions (HAPCs) were noted, and in one patient, low-amplitude propagating contractions (LAPCs) were noted. In one patient, propagating contractions were induced only when SNS was turned on. MI changes with SNS-on were variable among different patients with an increase in MI in two patients after turning SNS on and a decrease in the other two compared with baseline. Adverse effects following SNS placement remained minimal across all cases.</p><p><strong>Conclusion: </strong>This case series is the first to report SNS effects on colonic motility evaluated by HRCM in pediatrics. We demonstrate that propagating colonic contractions are promptly induced when SNS is turned on. Although the initial effects of SNS on colonic motility were observable, additional investigation is necessary to comprehend the fundamental mechanisms and long-term effectiveness of SNS in pediatric patients.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"236-242"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia. 沙特阿拉伯胃肠病学研究员的炎症性肠病培训评估。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 Epub Date: 2024-06-06 DOI: 10.4103/sjg.sjg_19_24
Hassan AlDhneem, Abdulelah AlMutairdi, Mashary Attamimi, Mahmoud Mosli, Turki AlAmeel, Badr Al-Bawardy

Background: Recent advancement and complexity in the management of inflammatory bowel disease (IBD) has made it challenging for gastroenterology (GI) fellows to obtain competency and confidence in managing the complex IBD patient. We aimed to evaluate the confidence and training in IBD among GI fellows in Saudi Arabia.

Methods: We conducted an electronic, voluntary, and anonymous multicenter survey study of GI fellows in Saudi Arabia, from 1/5/2023 to 1/9/2023. The survey evaluated the fellows' confidence level in IBD management, methods of training received, and the amount of additional training desired in 20 core IBD domains. GI fellows' preferred learning method was also evaluated.

Results: A total of 65 GI fellows responded to the survey. In the entire cohort, >50% of fellows reported low confidence in 7 out of 20 IBD management domains, which included 71% in managing j-pouch disorders, 67% in managing the elderly/frail patient with IBD, 60% in managing extraintestinal manifestations, 57% in recommending preventative health services, and 54% in counseling patients on small molecules. Receiving >4 IBD didactic sessions per year was significantly associated with high confidence in managing j-pouch disorders (44.4% vs 13.3%, P = 0.05) and managing the elderly/frail patient with IBD (86.7% vs 50.0%, P = 0.03). Doing an external rotation to expand IBD knowledge was associated with high confidence in managing the elderly/frail patient with IBD (100% vs 26.7%, P = 0.01).

Conclusion: Many GI fellows lacked confidence and training in key domains of IBD management. Enhancing IBD exposure with didactics and external rotations improved fellows' confidence in specific domains.

背景:炎症性肠病(IBD)治疗的最新进展和复杂性使胃肠病学(GI)研究员在管理复杂的 IBD 患者方面获得能力和信心面临挑战。我们的目的是评估沙特阿拉伯胃肠病学研究员对 IBD 的信心和培训情况:我们在 2023 年 5 月 1 日至 2023 年 9 月 1 日期间对沙特阿拉伯的消化科研究员进行了一次电子、自愿和匿名的多中心调查研究。调查评估了研究员对 IBD 管理的信心水平、接受培训的方法以及希望在 20 个核心 IBD 领域接受额外培训的数量。此外,还对消化内科研究员偏好的学习方法进行了评估:共有 65 名消化内科研究员回答了调查。在整个调查组中,超过 50% 的研究员表示对 20 个 IBD 管理领域中的 7 个领域信心不足,其中包括 71% 的研究员在管理 j 袋疾病方面信心不足,67% 的研究员在管理老年/体弱 IBD 患者方面信心不足,60% 的研究员在管理肠外表现方面信心不足,57% 的研究员在推荐预防性保健服务方面信心不足,54% 的研究员在为患者提供小分子药物咨询方面信心不足。每年接受四次以上的 IBD 教学课程与管理 j 袋疾病(44.4% vs 13.3%,P = 0.05)和管理 IBD 老年/体弱患者(86.7% vs 50.0%,P = 0.03)的高信心显著相关。进行外部轮转以扩展 IBD 知识与管理 IBD 老年/体弱患者的高信心相关(100% vs 26.7%,P = 0.01):结论:许多消化科研究员在 IBD 管理的关键领域缺乏信心和培训。结论:许多消化科研究员缺乏对 IBD 管理关键领域的信心和培训。通过教学和外部轮转加强对 IBD 的接触提高了研究员对特定领域的信心。
{"title":"Inflammatory bowel disease training assessment of gastroenterology fellows in Saudi Arabia.","authors":"Hassan AlDhneem, Abdulelah AlMutairdi, Mashary Attamimi, Mahmoud Mosli, Turki AlAmeel, Badr Al-Bawardy","doi":"10.4103/sjg.sjg_19_24","DOIUrl":"10.4103/sjg.sjg_19_24","url":null,"abstract":"<p><strong>Background: </strong>Recent advancement and complexity in the management of inflammatory bowel disease (IBD) has made it challenging for gastroenterology (GI) fellows to obtain competency and confidence in managing the complex IBD patient. We aimed to evaluate the confidence and training in IBD among GI fellows in Saudi Arabia.</p><p><strong>Methods: </strong>We conducted an electronic, voluntary, and anonymous multicenter survey study of GI fellows in Saudi Arabia, from 1/5/2023 to 1/9/2023. The survey evaluated the fellows' confidence level in IBD management, methods of training received, and the amount of additional training desired in 20 core IBD domains. GI fellows' preferred learning method was also evaluated.</p><p><strong>Results: </strong>A total of 65 GI fellows responded to the survey. In the entire cohort, >50% of fellows reported low confidence in 7 out of 20 IBD management domains, which included 71% in managing j-pouch disorders, 67% in managing the elderly/frail patient with IBD, 60% in managing extraintestinal manifestations, 57% in recommending preventative health services, and 54% in counseling patients on small molecules. Receiving >4 IBD didactic sessions per year was significantly associated with high confidence in managing j-pouch disorders (44.4% vs 13.3%, P = 0.05) and managing the elderly/frail patient with IBD (86.7% vs 50.0%, P = 0.03). Doing an external rotation to expand IBD knowledge was associated with high confidence in managing the elderly/frail patient with IBD (100% vs 26.7%, P = 0.01).</p><p><strong>Conclusion: </strong>Many GI fellows lacked confidence and training in key domains of IBD management. Enhancing IBD exposure with didactics and external rotations improved fellows' confidence in specific domains.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"260-265"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eosinophilic esophagitis: Current concepts in diagnosis and management. 嗜酸性粒细胞食管炎:当前的诊断和管理理念。
IF 1.9 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-07-01 Epub Date: 2024-05-16 DOI: 10.4103/sjg.sjg_50_24
Fahad I Alsohaibani, Musthafa C Peedikayil, Mohammed A Alzahrani, Nahla A Azzam, Majid A Almadi, Evan S Dellon, Abdulrahman A Al-Hussaini

Abstract: Eosinophilic esophagitis is an antigen-mediated chronic inflammatory disorder that has risen in incidence and prevalence over the past 2 decades. The clinical presentation is variable and consists of mainly esophageal symptoms such as dysphagia, heartburn, food impaction, and vomiting. Current management relies on dietary elimination, proton-pump inhibitors, and topical corticosteroids with different response rates and relapses after treatment discontinuation. With a better understanding of the underlying pathophysiology, many molecules emerged recently as targeted treatment including dupilumab (IL4/IL13 blocker), as the first FDA-approved biological treatment, which has changed the management paradigm.

摘要:嗜酸性粒细胞食管炎是一种抗原介导的慢性炎症性疾病,在过去 20 年中发病率和流行率不断上升。其临床表现多种多样,主要包括吞咽困难、烧心、食物嵌塞和呕吐等食道症状。目前的治疗主要依靠饮食控制、质子泵抑制剂和外用皮质类固醇,但反应率和停药后复发率各不相同。随着对潜在病理生理学的深入了解,最近出现了许多靶向治疗分子,其中包括杜比鲁单抗(IL4/IL13 阻断剂),它是第一种获得 FDA 批准的生物治疗方法,改变了治疗模式。
{"title":"Eosinophilic esophagitis: Current concepts in diagnosis and management.","authors":"Fahad I Alsohaibani, Musthafa C Peedikayil, Mohammed A Alzahrani, Nahla A Azzam, Majid A Almadi, Evan S Dellon, Abdulrahman A Al-Hussaini","doi":"10.4103/sjg.sjg_50_24","DOIUrl":"10.4103/sjg.sjg_50_24","url":null,"abstract":"<p><strong>Abstract: </strong>Eosinophilic esophagitis is an antigen-mediated chronic inflammatory disorder that has risen in incidence and prevalence over the past 2 decades. The clinical presentation is variable and consists of mainly esophageal symptoms such as dysphagia, heartburn, food impaction, and vomiting. Current management relies on dietary elimination, proton-pump inhibitors, and topical corticosteroids with different response rates and relapses after treatment discontinuation. With a better understanding of the underlying pathophysiology, many molecules emerged recently as targeted treatment including dupilumab (IL4/IL13 blocker), as the first FDA-approved biological treatment, which has changed the management paradigm.</p>","PeriodicalId":48881,"journal":{"name":"Saudi Journal of Gastroenterology","volume":" ","pages":"210-227"},"PeriodicalIF":1.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Saudi Journal of Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1